Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255-Reference-Cited by-同舟云学术

Phase II study of infusional chemotherapy with doxorubicin, vincristine and etoposide plus cyclophosphamide and prednisone (I-CHOPE) in resistant diffuse aggressive non-Hodgkin's lymphoma: CALGB 9255

Published:2000-09 Issue:9 Volume:11 Page:1141-1146
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lichtman S.M.,Niedzwiecki D.,Barcos T.L.,Carlisle M.,Cooper M.R.,Johnson J.L.,Peterson B.A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/11/9/1141/19478500/11-9-1141.pdf

Reference21 articles.

1. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma;Laport;Semin Oncol,1998

2. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma;Philip;N Engl J Med,1995

3. COPBLAM III: Incisional combination chemotherapy for diffuse large-cell lymphoma;Boyd;J Clin Oncol,1988

4. Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma;Carrion;Am J Clin Oncol,1995

5. Infusional chemotherapy for non-Hodgkin's lymphoma;Molldrem;Cancer Invest,1997

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?;Frontiers in Pharmacology;2023-05-04

2. Efforts in Bioprospecting Research: A Survey of Novel Anticancer Phytochemicals Reported in the Last Decade;Molecules;2022-11-28

3. Post-transplant lymphoproliferative disorders in lung transplant recipients: 20-yr experience at the University of Minnesota;Clinical Transplantation;2010-11-16

4. The Cancer and Leukemia Group B Pathology Committee at 50;Clinical Cancer Research;2006-06-01

5. The Cancer and Leukemia Group B Lymphoma Committee;Clinical Cancer Research;2006-06-01